CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?
Executive Summary
Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.
You may also be interested in...
AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.
Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate
In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.